Human butyrylcholinesterase (HuBChE) has previously been shown to protect mice, rats, and monkeys against multiple lethal toxic doses of organophosphorus (OP) anticholinesterases that were challenged by iv bolus injections. This study examines the concept of using a cholinesterase scavenger as a prophylactic measure against inhalation toxicity, which is the more realistic simulation of exposure to volatile OPs. HuBChE-treated awake guinea pigs were exposed to controlled concentration of soman vapors ranging from 417 to 430 /ig/liter, for 45 to 70 s. The correlation between the inhibition of circulating HuBChE and the dose of soman administered by sequential iv injections and by respiratory exposure indicated that the fraction of the inhaled dose of soman that reached the blood was 0.29. HuBChE to soman molar ratio of 0.11 was sufficient to prevent the manifestation of toxic signs in guinea pigs following exposure to 2.17x the inhaled LD50 dose of soman (ILD50, 101 /tg/kg). A slight increase in HuBChE:soman ratio (0.15) produced sign-free animals after two sequential respiratory exposures with a cumulative dose of 4.5 x ILD50. Protection was exceptionally high and far superior to the currently used traditional approach that consisted of pretreatment with pyridostigmine and postexposure combined administration of atropine, benactyzine, and an oxime reactivator. Quantitative analysis of the results suggests that in vivo sequestration of soman, and presumably other OPs, by exogenously administered HuBChE, is independent of the species used or the route of challenge entry. This assuring conclusion significantly expands the database of the bioscavenger strategy that now offers a dependable extrapolation from animals to human.
Protection against organophosphorus (OP) nerve agent poisoning consists of pretreatment with pyridostigmine (PYR) and ' Preliminary results were presented at the 5th International Meeting on Cholinesterase, Madras India, September [23] [24] [25] [26] [27] [28] 1994 . This work is in partial fulfillment of L. R.'s Ph.D. thesis (Hebrew University, Jerusalem, 1996) . 2 Current address: Faculty of Agriculture, The Hebrew University, Rehovot, Israel.
3 To whom correspondence should be addressed. E-mail: yacov@iibr.gov.il.
postexposure administration of atropine, oxime reactivator, and anticonvulsants (Dirnhuber et al, 1979; Dunn and Sidell, 1989; Shih et al, 1991) . Several drawbacks of this traditional multidrug therapy 4 prompted the search for new preventive strategies that will afford improved treatment over the existing therapeutic regimen. One approach is based on prophylactic bioscavengers that can rapidly dislodge OPs from the blood and afford reasonable solutions to the disadvantages of the current therapy. Cholinesterases (ChE) of various sources have been evaluated in recent years as new prophylactic agents due to their ability to rapidly sequester a wide range of toxic OPs (Wolfe et al, 1987; Ashani et al, 1991; Doctor et al, 1991; Broomfield et al, 1991; Maxwell et al, 1992; Brandeis et al, 1993; Raveh et al, 1993 Raveh et al, , 1997 . These studies enabled correlation of both the rate and the stoichiometry of OP sequestration with ChE blood levels and to demonstrate a remarkable protection, including alleviation of OP-induced behavioral deficits (Broomfield et al, 1991; Maxwell et al, 1992; Brandeis et al, 1993; Raveh et al, 1997) . Thus far, the evaluation of the antidotal efficacy of ChEs has been based on protection experiments in mice, rats, and monkeys and utilized the iv, im, and sc routes for the administration of the challenge.
The pharmacokinetics, the onset time, and severity of toxic manifestations following exposure to OPs depend not only on the animal species but also on the route of entry of the challenge (Sterri et al, 1982; Franz and Hilaski, 1990; Due et al, 1994; Benschop et al, 1995) . For example, Sterri et al. (1982) demonstrated that correlation between inhibition of brain acetylcholinesterase (AChE) and erythrocytes AChE could be observed only following iv injection, whereas significant inhibition was seen in the brain after ip, sc, or pc challenge, only when >90% of the erythrocytes AChE were inhibited. The authors demonstrated marked dependence of the rate of inhibition of erythrocytes AChE in guinea pigs, on the route of administration of sublethal doses of soman. In addition, the toxic isomers of soman were shown to be approximately twofold more persistent in blood after sc injection (Due et al, 1994) or vapor inhalation (Benschop et al, 1995) than after intravenous administration of the same dose in guinea pigs. This phenomenon was attributed to the slow release of soman from the sc injection site and lung tissues. The levels and the rate of appearance of an inhaled OP in blood are expected to determine the efficacy of an exogenous ChE in scavenging these toxins before they can reach threatening blood levels and inhibit physiologically important AChE. Since inhalation challenge is the more realistic simulation of exposure to volatile OPs, and since it is likely that the time course of inhaled OPs in blood will differ from that obtained after iv bolus injection, it was important to test the efficacy of prophylaxis with ChEs against inhalation intoxication with OP vapors.
The present study is the first analysis of the antidotal efficacy and the stoichiometry of detoxification of an inhaled OP, by pretreatment alone with exogenous ChE. Among the ChEs, butyrylcholinesterase of human plasma (HuBChE) appears to be a most suitable scavenging antidote candidate for use in humans Brandeis et al, 1993; . It does not produce untoward immunological or physiological responses following transfusions of plasma in humans, and no adverse reactions were reported after daily administration of partially purified HuBChE for several weeks (Cascio et al, 1988) . Further, HuBChE is stable for several days in the circulation of humans (Jenkins et al, 1967; Ostergard et al, 1988) . The protection afforded was tested here in HuBChE-loaded guinea pigs exposed to controlled concentrations of O-pinacolyl methylphosphonofluoridate (soman) vapors and compared with the efficacy of standard therapy that consisted of pretreatment with PYR and postexposure administration of mixture of 1,1 '-trimethylenebis-[(4-hydroximinomethyl) pyridinium dibromide](TMB 4 )-atropine-benactyzine mixture (TAB). The results offer an extended database for a dependable animal-to-human extrapolation of HuBChE prophylaxis against OP toxicity.
METHODS
Materials. Soman is a hazardous compound and all work with neat agent and concentrated solutions should be carried out in a well-ventilated hood under suitable safety precautions. The purity of soman (>95%) was determined by 'H and 31 P NMR spectroscopy and by a titration of a known amount of AChE from fetal bovine serum (Raveh et al, 1989) . HuBChE with specific activity of 700-800 units/mg was purified from outdated pooled human plasma, by affinity chromatography on procainamide-Sepharose 4B (Grunwalde/a/., 1997). One milligram of pure HuBChE contained approximately 12 nmol active sites.
HuBChE, soman, pyridostigmine bromide (Hoffmann La-Roche Inc., Nutley, NJ), TMB 4 , benactyzine HC1 (both from Aldrich Chemical Co., Milwaukee, WI), and atropine sulfate (Sigma Chemical Co., St. Louis, MO) were all dissolved in saline or in phosphate-buffered saline for iv and im injections.
Guinea pigs. Male albino Dunkin-Hartley guinea pigs weighing 340-370 g were purchased from IFFA-CREDO (France). Care and maintenance were in accordance with the principles described in the "Guide for Care and Use of Laboratory Animals" (NIH Publication 85-23, 1985) . The animals were housed in the animal colony of the Department of Pharmacology, and housing environment was controlled with constant temperature of 21°C, constant humidity, and a 12-h light/dark cycle. Food and water were available ad lib.
HuBChE Assay. Enzyme activity was determined by the method of Ellman et al. (1961) using butyryldiiocholine (BTC) as substrate, as previously described (Raveh el al., 1993) . One nanomole of HuBChE displayed approximately 60 units of enzyme activity.
Time course of HuBChE in the circulation. Endogenous activity of blood BChE was determined 10 to 20 min prior to the administration of HuBChE. At various time intervals following an im or iv bolus injection of the enzyme solution, 5 to 10 ^.1 heparinized blood samples was drawn from the toe vein, diluted 21-fold in distilled water, and assayed for HuBChE activity as described above. Calculations of units per milliliter plasma were based on a plasma to whole blood volume ratio of 0.53.
In vivo titration. Animals were administered iv (small saphenous vein) 0.2-0.5 ml solution of HuBChE in saline. Sequential iv injections of OPs in approximately 0.2 ml saline (at 10-to 15-min time intervals), started 1.5 h following the administration of the enzyme.
To determine HuBChE activity, hepannized blood samples were drawn from the toe vein 10 and 30 min after iv and inhalation exposure, respectively, and prior to each administration of soman and diluted 21-fold in distilled water. HuBChE assay was carried out as above.
Inhalation of soman. Awake guinea pigs were exposed to soman vapors in a modified inhalation apparatus designed and built as described elsewhere (Bitron and Aharonson, 1978) . The major modification was introducing plethysmographs which permitted the calculation of the actual inhaled dose of soman for individual guinea pig. The respiratory parameters, tidal volume (TV), minute volume (MV), and respiratory rate (RR), were calculated on line by a computer-aided program (Mezada, Israel). Precalibration was carried out with hydraulic pump that simulated normal TV and RR values of guinea pigs.
Briefly, the exposure system (built in a hood) operates under subatmospheric pressure (-5 cm water) and combines two separate passes of clean and soman-contaminated air. Soman vapors were switched into the system by pneumatic valves after 10 mm of animals' adaptation to the flow of clean air. Four animals were exposed simultaneously through a glass mask, in separate chambers connected with parallel flow lines. Each chamber served also as a whole body plethysmograph that enabled the monitoring of the respiratory parameters, before, during, and after the exposure. The mask compartment was isolated from the plethysmograph by inflatable latex sealing collar.
Exposure of naive animals or PYR-treated or HuBChE-treated guinea pigs to 120-430 /xg/liter soman endured 45-70 s, and the system was switched back to clean air for 10 min. At the end of each experiment animals were transferred to their home cages for blood sampling and monitoring gross behavior. The concentration of soman vapors was determined by specific Fluoride electrode (Coming, Science Products, U.S.A.) and enzymic assay based on inhibition of ChE. Samples of the inhaled air were collected during the exposure session from two outlets located before and after the breathing mask of each animal, at a flow rate of 4 liters/min. Collecting vehicles were 0.5 M KOH (for the Fluoride electrode assay) and 3:1 propylene glycol:water (for the enzymic assay). The efficiency of the collecting samplers was >96%.
A sham-handled control group was processed as above, except that the animals were exposed only to noncontaminated fresh air.
Calculation of the inhaled median lethal dose (ILDS0).
The inhaled dose was obtained by multiplying the inhaled volume during the exposure by the vapor concentration of soman. The inhaled dose was then normalized to body weight. The ILD50 in nonprotected guinea pigs was determined by using five groups of guinea pigs (n = 8 each), exposed to different concentrations of soman vapors (120 to 360 fig/liter) for 1 min, and calculated using the Spearman-Karber method (Finney, 1964) .
Drug administration. The guinea pigs were iv loaded with 2.5 to 12 mg HuBChE (30-144 nmol/animal) and approximately 90 min later exposed to soman vapors. One group of three animals was inhaled with soman vapors in three successive sessions at 45-to 60-min intervals. No posttreatment drug was given to the HuBChE-protected guinea pigs.
PYR-pretreated animals (im, 100 fig/kg, 30 min prior to exposure) were challenged with soman vapors and immediately treated with an im injection of a TAB that consisted of mixture of TMB4 (7.5 mg/kg), atropine sulfate (17.4 mg/kg), and benactyzine Ha (8.1 mg/kg) . 
RESULTS
Time course of HuBChE in guinea pigs. The clearance of enzyme from the blood following iv injection of 1600 units/ animal showed a multiphase behavior and the line in Fig. 1 was constructed in accordance with a biexponential decay equation . A rapid decrease in enzyme activity from the blood occurred immediately after iv bolus injection. HuBChE concentration was maintained essentially at a constant level between the first and the fifth hour postloading (Fig.  1, inset) . The following constants were obtained by a noncompartmental analysis of the pharmacokinetic data (NCOMP Version 2.7; Laub and Gallo., 1996) using the time dependence of HuBChE concentration in units per milliliter of plasma: mean residence time (MRT), 78 ± 6 h; total clearance (CL) 0.51 ± 0.06 ml/h • kg; volume of distribution at steady state (KJ, 39.8 ±1.9 ml/kg. Since we cannot rule out the possibility that HuBChE outside the plasma participates in the scavenging of soman, the initial distribution volume (approximated by the plasma volume, V p ) was compared with V M . V p (30.4 ±1.6 mlTkg) was obtained by dividing the iv administered dose by the extrapolated plasma HuBChE concentration to t = 0. Vŵ as found approximately 30% higher than V p , indicating that approximately one-third of the exogenously administered HuBChE may act as a scavenger in extravascular compartments.
The im time course was fitted to a triexponential equation, one exponent for the absorption and two for the clearance phase. The average peak blood HuBChE level following im loading of 2000 units/animal in three guinea pigs (C^^ = 34 ± 6 units/ml) was obtained at 15 ± 5 h. This level was maintained for approximately 30 h. The slope of the descending part was similar to that observed for the elimination phase following an iv injection. The bioavailability of HuBChE from the muscle was found 0.93 by dividing the area under the im curve (AUC) by the area under the iv time course (AUCs were normalized to the administered dose and body weight). The pharmacokinetics behavior of HuBChE in guinea pigs was found essentially similar to that observed in mice Saxena et al, 1997) , rats , and monkeys .
Effect of soman inhalation on the respiratory parameters.
The plethysmograph measurements were designed to enable the calculations of the actual inhaled dose during the exposure to soman vapors.
The TV, MV, and RR values of naive animals were found within the range reported previously for untreated resting guinea pigs (Guyton, 1947) . HuBChE did not significantly affect these parameters. The MV in nonprotected guinea pigs {n = 20) exposed to 120-360 jtg/liter soman for 60 s was found at 187 ± 49, 177 ± 33, and 226 ± 70 ml, before, during, and 1 min after the exposure to soman, respectively. These values are similar to those observed in control animals. When exposed to 417-430 /xg/liter soman for 45-70 s, HuBChEtreated animals {n = 11) displayed in general similar respiratory constants, namely, 189 ± 37, 159 ± 32, and 198 ± 59 ml, respectively. No changes in respiratory parameters were detected in 10 of 11 guinea pigs at 10 min postexposure of the HuBChE-protected group, and no breathing difficulties could be detected for at least 24 h after transferring the animals to their home cages.
It should be pointed out that in all cases observed during the first 10 to 15 s of exposure to the challenge, a transient slight decrease in TV and a slight increase in RR was seen, which accounted for an average of 10% decrease in MV, compared with fresh air. This minor reduction in the respiratory parameters during the flow of soman-contaminated air is attributed to an olfactory response (unpublished results).
In vivo titration of HuBChE by soman. In order to estimate the amount of soman that reached the blood, the stoichiometry of HuBChE inhibition was determined for iv sequential injections. To minimize loss of HuBChE due to its normal clearance from the circulation, exposure to soman was carried out between 1.5 and 4.5 h postloading of the enzyme (see Fig. 1 , inset). Figure 2 shows the iv titration curve of HuBChE in three individual guinea pigs. A linear relationship was observed between HuBChE residual activity and the dose of soman for as high as 80% of the initial concentration of the enzyme. Assuming an average whole blood volume of 21 ml/animal, approximately 64 nmol soman was required to completely inhibit 1390 units or 23 nmol of circulating HuBChE/animal (Fig. 2, dotted line) .
Protection achieved. Table 1 shows data for individual HuBChE-treated guinea pigs and demonstrates the dependency between the initial HuBChE to soman molar ratio and the prophylactic efficiency of the exogenous enzyme. No posttreatment therapy was administered at any time. The experiments started with inhalation of 260-511 nmol soman (group A, 1.29-2.53 X ILD50; see also Table 2), while the total blood content of HuBChE was at 28.3 to 35.2 nmol/guinea pigs. An increase in the concentration of circulating HuBChE (group B, 38.4 to 47.5 nmol/animal) while maintaining a similar level of inhaled soman improved protection. On the whole, of the first eight guinea pigs that were challenged with a single exposure to soman, five animals seemed unaffected, two experienced light fasciculations and ataxia that disappeared within 1 h, and one died. The initial molar ratio of HuBChE to soman vapors that was sufficient to confer a sign-free protection against as high as 2.17 X ILD50 soman was 0.11. The inability to protect animal A-2 is attributed to the exceptionally low HuBChE: soman ratio (0.061).
Manifestation of toxic signs following successive exposures (group C) occurred only after the third challenge. The initial HuBChE content was 123.5 to 133.9 nmol/animal. Animal C-l was exposed to a cumulative dose of 3.63 X ILD50 and showed mild salivation only after the third exposure that disappeared within 60 min. Animal C-2 inhaled 5.24X ILD50 and did not display any of the typical toxic signs of soman poisoning immediately after the exposure or at any later time. Guinea pig C-3 died within 5 min after the third exposure that amounted to 5.32X ILD50 soman. No toxic signs were observed after the Table 2 ).
* Slight fasciculations and light ataxia. Disappeared within 60 min.
•^Cumulative inhaled dose over three successive exposures. Figures in parentheses are 95% confidence limits. * Determined in female albino guinea pigs weighing 400-600 g (Sterri et aL, 1982) .
c Reported for male albino Dunkin-Hurtley guinea pigs weighing 370-430 g (Due et aL, 1993) .
d PYR administered im 30 min prior to exposure and TAB mixture injected im immediately after the administration of the challenge (for details see Methods). Table 2 ). Based on observations made during the determination of the ILD50 it was concluded that 0.7 X ILD50 soman is a maximal sign-free dose in nonprotected guinea pigs. Since the duration of the toxic isomers of soman in blood after respiratory exposure in guinea pigs is approximately two-fold greater than after iv injection (Benschop et ai, 1995) , it was assumed that the inhibition of circulating HuBChE following inhalation exposure can amply be rendered to soman concentration in blood, on the basis of the iv titration curve. Thus, the total calculated capacity of HuBChE to sequester inhaled soman was based on the following summation (in nmol/animal): 0.7 X 202 + 2.8 X the HuBChE blood content. Table 3 compares the calculated protection with the actual inhaled dose in animals that were either sign-free or showed only minor toxic signs which waned within a short period following exposure to soman. In general, the actual inhaled dose was slightly higher than the calculated values which were predicted to prevent manifestations of toxic signs. This phenomenon can be attributed to the gradual introduction of soman vapors to HuBChE in blood.
The fraction of soman vapors that entered the blood. Estimates of soman that reached the blood were based on the assumption that a loss of 1 nmol HuBChE resulted from an entry of approximately 2.8 nmol of the challenge into the circulation. A reasonable linear correlation was obtained between the amount of soman that reached the blood and the inhaled dose of soman, for up to approximately 450 nmol soman/animal. The slope of the dotted line (Fig. 3, 0 .29 at r 2 = 0.84) was found in close agreement with the average ratio, LD5Oiv/ILD5O (0.25; Table 2 ) and suggests that approximately 25% of the inhaled dose of racemic soman reached the blood, compared to an iv injection of a similar dose. Increasing the dose of inhaled soman above 450 nmol soman/animal revealed a slight break in the curve that indicates the beginning of a nonlinear increase in the fraction of inhaled soman that was sequestered by HuBChE. This may be attributed to intensified escape of soman from the various binding sites located along die respiratory tract, due to die increased inflow of soman vapors.
The essentially linear relationship between the sequestered vs inhaled dose of soman over a HuBChE concentration range of 28 to 134 nmol/animal, together widi the fact that animals were practically free of postexposure toxic signs, imply that sufficient amount of scavenger was available to alleviate soman toxicity that would have been manifested in unprotected guinea pigs.
Protective ratio of PYR-TAB treatment. Table 2 summarizes the median lethal dose of soman administered via iv, im, and inhalation routes in guinea pigs and in PYR-treated animals that were administered TAB immediately after the exposure to the challenge. The standard therapeutic regimen PYR-TAB conferred 5 of 5.56 when the challenge was injected im, compared to 2.22 when soman was introduced through the respiratory tract It should be pointed out that in contrast to HuBChE-treated animals, PYR-treated guinea pigs that survived the inhalation challenge showed severe toxic signs for several hours, even after treatment with TAB.
DISCUSSION
This study demonstrates for the first time the ability of an exogenously administered bioscavenger to alleviate inhalation toxicity induced by a potent nerve agent, without the need for a posttreatment therapy. Of all antidote regimens tested in our laboratory, prophylaxis alone with HuBChE afforded an almost perfect protection against inhalation toxicity of soman. Protection with HuBChE was superior to the standard antidote regimen that consisted of pretreatment with PYR and posttreatment with TAB. The results from this study clearly demonstrate that the same biochemical rational determines the quantitative parameters of the antidotal efficacy of HuBChE, irrespective of the route of entry of the challenge. In addition, the observed fraction of inhaled soman that reached the blood provided explanation for the fourfold increase in the inhaled median lethal dose of soman relative to the iv LD50 in guinea pigs.
The stoichiometry of soman vapors sequestration. The in vitro stoichiometry of the inhibition of HuBChE was established at 1 nmol active site of the enzyme per 1.2 nmol soman , whereas in guinea pigs extrapolation showed that 1 nmol HuBChE was inhibited only after the sequential injections of a cumulative dose of 2.8 nmol soman. To explain the apparent discrepancy, reported variations in the toxicokinetics of the components of the racemic mixture of soman need to be considered. While only two of the four stereoisomers of soman denoted, C(+)P(-) and C(-)P(-) inhibit AChE, 6 HuBChE is further inhibited under certain conditions of in vitro titration by one of the two nontoxic isomers C(+)P(+) and C(-)P(+) (Keijer and Wolring, 1969; Raveh et al., 1993) . Since the C(±)P(+) isomers are substantially less stable both in vivo and ex vivo plasma than the P(-) constituents (Due et al., 1994; Benschop and de Jong, 1991) , it is suggested that one of the P(+) isomers that inhibited HuBChE in vitro contributed only a minor fraction to the observed in vivo inhibition by racemic soman.
In addition to the stereoselectivity factor, the increase in the soman dose that was required to inhibit the enzyme in vivo relative to the in vitro titration is attributed to (a) the presence of endogenous scavengers or (b) to a rapid clearance of soman from the blood or to a combination of both factors. This is evidenced by the bending of the in vivo titration curve after the fifth injection, suggesting that when blood HuBChE level decreased below a certain level, other pathways dominate soman detoxification. The persistency of the toxic isomers of soman in blood of carboxylesterase (CaE)-inhibited guinea pigs is characterized by an initial half-life of 27 s and a terminal phase half-life of elimination of 38 to 46 min (Due et al, 1993) . Under the experimental conditions described here it was expected that 1 /xM HuBChE will sequester within 2 s 95% of soman dose that produced a blood concentration of 0.25 /JM . Therefore, it is concluded that under the described conditions of the in vivo titration, the parallel reaction with endogenous scavengers rather than the rate of clearance of soman from the circulation is responsible for the relatively low HuBChE:soman ratio.
The stoichiometry of sequestration of soman was previously determined in several species. One nanomole soman injected iv inhibited 0.32, 0.25, and 0.65 nmol circulating HuBChE in mice, rats , and monkeys , respectively, compared with 0.36 nmol in guinea pigs. The results with mice, rats, and monkeys parallel species variations in the level of the endogenous scavenger CaE (Maxwell et al, 1987; Stern and Fonnum, 1989) . However, the profound decrease in CaE content of guinea pigs compared with mice and rats did not seem to increase the amount of inhibited HuBChE, as was observed in monkeys that contain the lowest level of CaEs among the tested animals. We explain this lack of consistency by the fact that the kinetics of the in vivo sequestration of the challenge is under near stoichiometry conditions. Since the initial molar concentrations of HuBChE in mice and rats were five-and three-fold greater, respectively, than in guinea pigs, the sequestration pathway of soman in mice was favored by HuBChE despite the high CaE levels in this species. Thus, the combined detoxification by endogenous and exogenous scavengers in the two species resulted in a similar molar ratio of HuBChE to soman that was required to inhibit the enzyme in vivo. The above iv-based considerations together with previously published data Brandeis et al, 1993; Raveh et al, 1993 Raveh et al, , 1997 clearly show that exogenous administration of HuBChE increases soman detoxification as would be expected from the enzyme blood levels, irrespective of the endogenous capacity to hydrolyze soman. This conclusion is important for a safe and reliable extrapolation from animals to humans who contain, if at all, low activity of serum CaE. Monitoring blood concentration of the exogenous enzyme appears to be sufficient to predict protection levels against inhalation toxicity of OPs that are potent inhibitors of HuBChE (e.g., soman, sarin, GF, tabun, VX, paraoxon).
Efficacy of HuBChE prophylaxis. The protection experiments were designed to provide information on the minimal quantity of HuBChE that is required to protect guinea pigs against approximately 2X ILD50 doses of soman vapors. Signfree protected animals were seen using HuBChE:soman molar ratio as low as 0.11, without the need for posttreatment therapy. Maxwell et al. (1993) demonstrated that FBS-AChE in mice was superior to either pretreatment with PYR-atropine or posttreatment with HI6-atropine, in alleviation of postexposure incapacitation 24 h after subcutaneous injection of soman. However, the high ratio of FBS AChE to soman applied in these experiments (1.19), and the use of CaE-inhibited mice, precluded direct comparison with the results obtained with HuBChE.
Unlike in a bolus iv injection, inhalation exposure introduces soman gradually into the circulation and the initial molar concentration of the challenge in the blood should be smaller then the concentration produced by the same dose administered iv at once. The slow introduction of the inhaled OP to the circulating scavenger increases the efficiency of soman sequestration to below its toxic blood levels, relative to a bolus iv challenge. Since the predicted protection was based on the iv titration curve, the above considerations explain the enhanced protection found in most of soman-inhaled HuBChE-treated guinea pigs, over the calculated values (Table 3) .
The importance of prevention of even a single episode of OP toxicity is implied in numerous publications. For example, an ex vivo examination of rat tracheal smooth muscle after 10 min of in vivo inhalation of soman led to the conclusion that PYR pretreatment together with posttreatment with the oximes HI6 or toxogonin improved the recovery of the impaired tracheal muscle, but could not prevent its reduced contractility. Further, the same authors showed that PYR pretreatment, though it produced significant recovery of plasma ChE activity, did not protect the enzyme in the trachea and the lung (Walday et al, 1993) . Maxwell et al. (1993) showed that standard treatment with PYR-atropine-HI6 could not alleviate incapacitation in mice 24 h after subcutaneous challenge of soman. Partial masking of endogenous AChE by pretreatment with phosphoroamidates that provide an extended protection of AChE relative to PYR increased survival ratio in soman-challenged guinea pigs only if atropine was administered prior to the sc injection of soman (Langenberg et al, 1996) . By contrast to the conventional therapeutic approaches, prophylaxis alone with HuBChE was shown here not only to increase substantially survival ratio, but also to prevent postexposure signs in surviving animals.
Conclusions. Three important factors can now be added to the database of OP bioscavengers: (a) the finding that the stoichiometry of the protection against inhalation exposure agrees reasonably with that seen after iv challenge, (b) the consistency of the protection results across four species, and (c) the similar pharmacokinetic behavior of HuBChE in mice, rats, guinea pigs, and rhesus monkeys. Species variation in a combined oxime-carbamate protection against OP poisoning (Maxwell et al, 1988; Maxwell and Brecht, 1991) raises some uncertainties in extrapolation of optimal regimen drug treatments from animal to humans. In that respect, the expanded database on cholinesterases as prophylactic measures highlights another advantage of the bioscavenger strategy. Thus, results with HuBChE offer now a reliable animal-to-human extrapolation of the level of protection against nerve agent toxicity, by simple determination of HuBChE blood concentration.
